Document:

Amendment #1 to the Commercialization Agreements

 Exhibit 10.25 
 AMENDMENT NO. 1 TO THE COMMERCIALIZATION AGREEMENTS 
 Animas Corporation, a Delaware Corporation, having a principal place of business at 200 Lawrence Drive, West Chester, PA 19380 (“Animas”) and DexCom, Inc., a Delaware corporation, having a principal place of business at
6340 Sequence Drive, San Diego, CA 92121 (“DexCom”), are parties to the Commercialization Agreement dated July 31, 2008 (the “US Commercialization Agreement”) and the OUS Commercialization Agreement dated
January 12, 2009 (the “OUS Commercialization Agreement”). Capitalized terms not defined in this Amendment No. 1 to the Commercialization Agreements (the “Amendment”) shall have the meanings given to them in the US
Commercialization Agreement or OUS Commercialization Agreement, as applicable. 
 WHEREAS, simultaneously herewith, the parties
are entering into an amendment to their Amended and Restated Joint Development Agreement dated January 12, 2009 (as amended, the “Joint Development Agreement”) in order to conduct some additional development work on the Hybrid
Transmitter (as defined in the Joint Development Agreement and hereinafter the “Hybrid Transmitter”); and 
 WHEREAS,
the parties desire to amend each of the US Commercialization Agreement and the OUS Commercialization Agreement in order to reflect certain changes related to the Hybrid Transmitter as well as other commercial matters; 
 NOW THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth, the parties agree as follows:

 1. Changes to Definitions: 
 (a) The definition of “Transmitter” in both the US Commercialization Agreement and the OUS Commercialization Agreement is hereby amended to include, without limitation, the Hybrid Transmitter. 
 (b) The definitions of “Embedded System,” “Sensor,” “Software” and “Transmitter in the US
Commercialization Agreement are hereby amended to add the following text at the end of such definitions: “, including any improvements and successor products included as part of the Integrated System pursuant to Section 2 of the Joint
Development Agreement.” 
 (c) The definition of “Enabled Pump” in the US Commercialization Agreement is hereby
amended to add the following text at the end of such definition: “, and each future insulin pump system, if any, developed by Animas for use as part of an Integrated System.” 
 (d) The definition of “Integrated System” in the US Commercialization Agreement is hereby amended to add the following text at the
end of the first sentence of such definition: “and any future such system developed under the Joint Development Agreement.” 
 2. The
second sentence of Section 2.02(a) of the US Commercialization Agreement is hereby amended and restated in its entirety as follows: “For the avoidance of doubt, the license granted by this Section 2.02(a) shall extend during the term
of this Agreement and shall survive any

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  
 
termination of this Agreement until such time as (i) Animas decides, in its sole discretion, to discontinue marketing and sales of the Enabled Pump (or successor product) and
(ii) Animas fulfills all customer service and warranty obligations with respect to such Enabled Pumps.” 
 3. The US Commercialization
Agreement is hereby amended to add a new section 2.05 as follows: 
 “2.05 Hybrid Transmitter Exclusivity. Without
the prior written consent of Animas, DexCom shall not, directly or indirectly, sell or provide any rights (including by means of a license) to the Hybrid Transmitter or any derivative transmitter product utilizing [*****] to any third party or its
Affiliates (including any third party that may acquire all or part of DexCom’s business) that makes or sells devices in the Territory that are capable of delivering insulin continuously and subcutaneously.” 
 4. The OUS Commercialization Agreement is hereby amended to add a new section 2.04 as follows: 
 “2.04 Hybrid Transmitter Exclusivity. Without the prior written consent of Animas, DexCom shall not, directly or indirectly,
sell or provide any rights (including by means of a license) to the Hybrid Transmitter or any derivative transmitter product utilizing [*****] to any third party or its Affiliates (including any third party that may acquire all or part of
DexCom’s business) that makes or sells devices in the Territory that are capable of delivering insulin continuously and subcutaneously. Nothing in this Section 2.04 shall limit any of DexCom’s obligations under
Section 2.01(e).” 
 5. Sections 5.01(a) and (c) of the US Commercialization Agreement are hereby amended and restated in their
entirety as follows: 
 “(a) Each party shall determine in its sole discretion whether the Integrated System shall be launched commercially
in the Territory. If the parties disagree, they will refer the disagreement to the President of Animas and the President and CEO of DexCom for discussion. If such officers are not able to reach an agreement within [*****]of the referral to them of
the disagreement, neither party will be obligated to launch the Integrated System in the Territory. If the parties agree upon the commercial launch of the Integrated System in the Territory, the Commercialization Steering Committee will be
responsible for selecting the Commercial Launch Date. Notwithstanding the foregoing, if Animas desires to launch the Integrated System in the Territory and DexCom does not, then, subject to Animas’ fulfillment of its financial responsibilities
under Section 3.2 of the Joint Development Agreement, Animas may proceed with such launch, and DexCom shall use its commercially reasonable efforts to support such launch throughout the Term of this Commercialization Agreement, including by
supplying Sensors and Transmitters to users of the Integrated System and otherwise fulfilling its obligations under this Commercialization Agreement.” 
 “(c) DexCom shall be solely responsible for the sales of the Starter Kits, Sensors and Transmitters and shall determine the pricing of the Sensors and Transmitters in its sole discretion.
Notwithstanding the foregoing, the Commercialization Steering Committee may establish a framework under which the Animas sales organization shall distribute the

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  
 
Transmitter. The pricing of the Starter Kits shall be determined in accordance with Section 3.03. DexCom shall determine in its sole discretion and in accordance with its normal business
practices the amount of resources that it shall expend on sales activities for Integrated System (subject to the obligation to support the commercial launch of the Integrated System in accordance with Section 5.01(a)). Following the commercial
launch of the Integrated System, DexCom shall make Sensors available for sale to purchasers of the Integrated System that are compatible with the Hybrid Transmitter for a period beginning on such launch and lasting [*****] (unless DexCom agrees to a
longer period) following the first commercial sale of DexCom’s first Transmitter released subsequently to the Hybrid Transmitter (“Next-Gen Transmitter”); provided, that if the Next-Gen Transmitter has not been launched prior
to the expiration or termination of this Commercialization Agreement, then DexCom shall make Sensors available for sale to purchasers of the Integrated System for a period of [*****] (unless DexCom agrees to a longer period) from the date of
expiration or termination (such period of Sensor supply being the “Sensor Supply Period”). For the avoidance of doubt, the supply obligation set forth in the immediately prior sentence shall survive any expiration or termination of
this Agreement.” 
 6. Section 5.01(a) of the OUS Commercialization Agreement is hereby amended to add the following text at the end:

 “Following the commercial launch of the Integrated System, DexCom shall supply Sensors that are compatible with the Hybrid Transmitter
for a period beginning on such launch and lasting [*****] (unless DexCom agrees to a longer period) following the first commercial sale of DexCom’s Next-Gen Transmitter; provided, that if the Next-Gen Transmitter has not been launched prior to
the expiration or termination of this Commercialization Agreement, then DexCom shall supply such Sensors for a period of [*****] (unless DexCom agrees to a longer period) from the date of expiration or termination (such period of Sensor supply being
the “Sensor Supply Period”). For the avoidance of doubt, the supply obligation set forth in the immediately prior sentence shall survive any expiration or termination of this Agreement.” 
 7. Section 6.06 of the US Commercialization Agreement is hereby amended to add the following text at the end: 
 “The parties’ obligations under the Quality Agreement shall survive termination of this Agreement to the extent necessary to allow each party to
fulfill any post-termination customer service, warranty and regulatory obligations with respect to the Integrated System, and they shall reasonably cooperate with one another to allow each such party to fulfill such obligations, including by
providing any information reasonably requested by a party. In addition, following termination of this Agreement, DexCom will continue to perform its regulatory obligations regarding the Integrated System such that Animas is able to continue to sell
and promote the Enabled Pump. DexCom shall also prepare and file, at Animas’ expense, all required PMA supplements modifying the Integrated System as approved at the time of termination of this Agreement solely to accommodate changes affecting
the safety and efficacy of the Enabled Pump (as opposed to feature changes).” 
 8. Section 6.06 of the OUS Commercialization
Agreement is hereby amended to add the following text at the end: 

 “The parties’ obligations under the Quality Agreement shall survive termination of this Agreement
to the extent necessary to allow each party to fulfill any post-termination customer service, warranty and regulatory obligations with respect to the Integrated System, and they shall reasonably cooperate with one another to allow each such party to
fulfill such obligations, including by providing any information reasonably requested by a party. In addition, following termination of this Agreement, DexCom will continue to perform its regulatory obligations regarding the Integrated System such
that Animas is able to continue to sell and promote the Enabled Pump. DexCom shall also prepare and file, at Animas’ expense, all required regulatory amendments modifying the Integrated System as approved at the time of termination of this
Agreement solely to accommodate changes affecting the safety and efficacy of the Enabled Pump (as opposed to feature changes).” 
 9.
Article 10 of the US Commercialization Agreement is hereby amended and restated in its entirety as follows: 
 “The initial
term of this Commercialization Agreement shall commence upon execution and extend for 3 years (the “Initial Term”) from the Commercial Launch Date, but no later than 3 years after December 31, 2010. At the end of the fourth
year of the Initial Term, an additional year shall be added to the Term, unless either party gives the other party written notice prior to that date that it intends to terminate this Commercialization Agreement at the end of the Initial Term.
Thereafter, a year shall automatically be added to the end of the then current Term at such date as is one year prior to the end of the then current term, unless either party gives the other party written notice by such date that it desires to
terminate this Commercialization Agreement at the end of such Term. The Initial Term along with any extensions shall be referred to in this Commercialization Agreement as the “Term.”” 
 10. Article 10 of the OUS Commercialization Agreement is hereby amended and restated in its entirety as follows: 
 “The initial term of this Commercialization Agreement shall commence upon execution and extend for 3 years (the “Initial
Term”) from the Commercial Launch Date, but no later than 3 years after December 31, 2010. At the end of the fourth year of the Initial Term, an additional year shall be added to the Term, unless either party gives the other party
written notice prior to that date that it intends to terminate this Commercialization Agreement at the end of the Initial Term. Thereafter, a year shall automatically be added to the end of the then current Term at such date as is one year prior to
the end of the then current term, unless either party gives the other party written notice by such date that it desires to terminate this Commercialization Agreement at the end of such Term. The Initial Term along with any extensions shall be
referred to in this Commercialization Agreement as the “Term.”” 
 11. The first sentence of Section 11.05(b) of the
US Commercialization Agreement is hereby amended and restated in its entirety as follows: 
 “On expiration or termination of this
Agreement, Animas shall be permitted to sell and promote Enabled Pumps that bear the DexCom Trademarks until the end of the Sensor Supply Period.” 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  
 12. The first sentence of Section 11.05(b) of the OUS Commercialization Agreement is hereby amended and restated in its entirety as follows: 

“On expiration or termination of this Agreement, Animas shall be permitted to sell and promote: (i) Enabled Pumps that bear the DexCom
Trademarks until the end of the Sensor Supply Period and (ii) Sensors and Transmitters that bear the DexCom Trademarks for a period of [*****] (or such longer period as the Commercialization Steering Committee may agree upon).” 

13. Section 18.06 of the US Commercialization Agreement is hereby amended by adding the following sentence at the end: 
 “Subject to the foregoing sentence, this Commercialization Agreement shall bind and inure to the benefit of the parties hereto and each of their
respective successors and assigns.” 
 14. Section 18.12 of the US Commercialization Agreement is hereby amended by adding
Section 3.04 to the list of sections that survive termination. 
 15. Other than as expressly modified by this Amendment No. 1, the US
Commercialization Agreement and the OUS Commercialization Agreement shall remain unchanged and in full force and effect. 
 [Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to be signed by duly authorized
officers or representatives as of the date first above written. 
  

									
	DEXCOM, INC.	 		 	ANIMAS CORPORATION
					
	By:	 	 /s/ Steven R. Pacelli
	 		 	By:	 	 /s/ Eric Schwartz

					
	Print Name:	 	 Steven R. Pacelli
	 		 	Print Name:	 	 Eric Schwartz

					
	Title:	 	 Chief Administrative Officer
	 		 	Title:	 	 V.P. & General Counsel

					
	Date:	 	 July 30, 2009
	 		 	Date:	 	 July 30, 2009Assignment and Acceptance Agreement, dated September 16, 2009.

 Exhibit 10.1 
 ASSIGNMENT AND ACCEPTANCE AGREEMENT 
 This
ASSIGNMENT AND ACCEPTANCE AGREEMENT (this “Assignment and Acceptance”) dated as of September 16, 2009 is made between THE CIT GROUP/BUSINESS CREDIT, INC. (the “Assignor”) and WACHOVIA BANK,
NATIONAL ASSOCIATION (the “Assignee”). 
 RECITALS 
 WHEREAS, the Assignor is party to that certain Second Amended and Restated Credit Agreement dated as of October 2, 2006 (as amended,
amended and restated, modified, supplemented or renewed, the “Credit Agreement”) among Kforce Inc., a Florida corporation, and certain of its Subsidiaries, as borrowers (the “Borrowers”), certain of Borrowers’
Affiliates, the several financial institutions from time to time party thereto (including the Assignor, the “Lenders”), and Bank of America, N.A., as Administrative Agent for the Lenders (the “Administrative
Agent”). Any terms defined in the Credit Agreement and not defined in this Assignment and Acceptance are used herein as defined in the Credit Agreement; 
 WHEREAS, as provided under the Credit Agreement, the Assignor has committed to making Loans (the “Committed Loans”) to the Borrowers in an aggregate amount not to exceed $35,000,000 (the
“Commitment”); 
 WHEREAS, the Assignor has made Committed Loans in the aggregate principal amount of
$4,015,000 to the Borrowers; 
 WHEREAS, the Assignor has acquired a participation in its pro rata share of the Lenders’
liabilities under Letters of Credit in an aggregate principal amount of $1,227,524.32 (the “L/C Obligations”); and 
 WHEREAS, the Assignor wishes to assign to the Assignee part of the rights and obligations of the Assignor under the Credit Agreement in respect of its Commitment, together with a corresponding portion of each of its outstanding Committed
Loans and L/C Obligations, in an amount equal to $20,000,000 (the “Assigned Amount”) on the terms and subject to the conditions set forth herein and the Assignee wishes to accept assignment of such rights and to assume such
obligations from the Assignor on such terms and subject to such conditions; 
 NOW, THEREFORE, in consideration of the foregoing
and the mutual agreements contained herein, the parties hereto agree as follows: 
 1. Assignment and Acceptance. 
 (a) Subject to the terms and conditions of this Assignment and Acceptance, (i) the Assignor hereby sells, transfers and assigns to the
Assignee, and (ii) the Assignee hereby purchases, assumes and undertakes from the Assignor, without recourse and without representation or warranty (except as provided in this Assignment and Acceptance) 57.1428571% (the “Assignee’s
Assigned Percentage Share”) of (A) the Commitment, the Committed Loans and the L/C Obligations of the Assignor and (B) all related rights, benefits, obligations, liabilities and indemnities of the Assignor under and in connection
with the Credit Agreement and the Loan Documents. 

 (b) With effect on and after the Effective Date (as defined in Section 5 hereof), the
Assignee shall be a party to the Credit Agreement and succeed to all of the rights and be obligated to perform all of the obligations of a Lender under the Credit Agreement, including the requirements concerning confidentiality and the payment of
indemnification, with a Commitment in an amount set forth in Section 1(c). The Assignee agrees that it will perform in accordance with their terms all of the obligations which by the terms of the Credit Agreement are required to be performed by
it as a Lender. It is the intent of the parties hereto that the Commitment of the Assignor shall, as of the Effective Date, be reduced by an amount equal to the Assigned Amount and the Assignor shall relinquish its rights and be released from its
obligations under the Credit Agreement to the extent such obligations have been assumed by the Assignee; provided, however, the Assignor shall not relinquish its rights under Sections 4.4 and 14.11 of the Credit Agreement to the extent such rights
relate to the time prior to the Effective Date. 
 (c) After giving effect to the assignment and assumption set forth herein, on
the Effective Date the Assignee’s Commitment will be $50,000,000. 
 (d) After giving effect to the assignment and
assumption set forth herein, on the Effective Date the Assignor’s Commitment will be $15,000,000. 
 2. Payments.

 (a) As consideration for the sale, assignment and transfer contemplated in Section 1 hereof, the Assignee shall pay to
the Assignor on the Effective Date in immediately available funds an amount equal to $2,294,285.71, representing the Assignee’s Assigned Percentage Share of the principal amount of all Committed Loans. 
 (b) The Assignee further agrees to pay to the Administrative Agent a processing fee in the amount specified in Section 11.2(a) of the
Credit Agreement. 
 3. Reallocation of Payments. 
 Any interest, fees and other payments accrued to the Effective Date with respect to the Commitment, and Committed Loans and L/C Obligations shall be for the account of the Assignor. Any interest, fees and
other payments accrued on and after the Effective Date with respect to the Assigned Amount shall be for the account of the Assignee. Each of the Assignor and the Assignee agrees that it will hold in trust for the other party any interest, fees and
other amounts which it may receive to which the other party is entitled pursuant to the preceding sentence and pay to the other party any such amounts which it may receive promptly upon receipt. The Assignor and the Assignee shall make all
appropriate adjustments in payments by the Administrative Agent for periods prior to the Effective Date or with respect to the making of this assignment directly between themselves. 
 4. Independent Credit Decision. 
 The Assignee (a) acknowledges that it has received a copy of the Credit Agreement and the Schedules and Exhibits thereto, together with copies of the most recent financial statements of the
Borrowers, and such other documents and information as it has deemed appropriate to make its own credit and legal analysis and decision to enter into this Assignment and Acceptance; and (b) agrees that it will, independently and without
reliance upon the Assignor, the Administrative Agent or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit and legal decisions in taking or not taking action under
the Credit Agreement. 
  

 2 

 5. Effective Date; Notices. 
 (a) As between the Assignor and the Assignee, the effective date for this Assignment and Acceptance shall be September 16, 2009 (the
“Effective Date”); provided that the following conditions precedent have been satisfied on or before the Effective Date: 
 (i) this Assignment and Acceptance shall be executed and delivered by the Assignor and the Assignee; 
 (ii) the consent of the Administrative Agent required for an effective assignment of the Assigned Amount by the Assignor to the Assignee shall have been duly obtained and shall be in full force and effect
as of the Effective Date; 
 (iii) payment by the parties hereto of all amounts due in connection with this
Assignment and Acceptance and transfer of the Assigned Amount; and 
 (iv) the processing fee referred to in
Section 2(b) hereof and in Section 11.2(a) of the Credit Agreement shall have been paid to the Administrative Agent. 
 (b) Promptly following the execution of this Assignment and Acceptance, the Assignor shall deliver to the Borrowers and the Administrative Agent for acknowledgment by the Administrative Agent, a Notice of Assignment in the form attached
hereto as Schedule 1. 
 6. [Intentionally omitted.] 
 7. Withholding Tax. 
 The Assignee (a) represents and warrants to the Lender, the Administrative Agent and the Borrowers that under applicable law and treaties no tax will be required to be withheld by the Lender with respect to any payments to be made to
the Assignee hereunder, (b) agrees to furnish (if it is organized under the laws of any jurisdiction other than the United States or any State thereof) to the Administrative Agent and the Borrowers prior to the time that the Administrative
Agent or Borrowers are required to make any payment of principal, interest or fees hereunder, duplicate executed originals of either U.S. Internal Revenue Service Form W-8ECI or U.S. Internal Revenue Service Form W-8BEN (wherein the Assignee claims
entitlement to the benefits of a tax treaty that provides for a complete exemption from U.S. federal income withholding tax on all payments hereunder) and agrees to provide new Forms W-8ECI or W8BEN upon the expiration of any previously delivered
form or comparable statements in accordance with applicable U.S. law and regulations and amendments thereto, duly executed and completed by the Assignee, and (c) agrees to comply with all applicable U.S. laws and regulations with regard to such
withholding tax exemption. 
 8. Representations and Warranties. 
 (a) The Assignor represents and warrants that (i) it is the legal and beneficial owner of the interest being assigned by it hereunder
and that such interest is free and clear of any Lien or other adverse claim; (ii) it is duly organized and existing and it has the full power and authority to take, and has taken, all action necessary to execute and deliver this Assignment and
Acceptance and any other documents required or permitted to be executed or delivered by it in connection with this Assignment and Acceptance and to fulfill its obligations hereunder; (iii) no notices to, or consents, authorizations or approvals
of, any Person are required (other than any already given or obtained) for its due execution, delivery and performance of this Assignment and Acceptance, and apart from any agreements or undertakings or filings required by the Credit Agreement, no
further action by, or notice to, or filing with, any Person is required of it for such execution, delivery or performance; and (iv) this Assignment and Acceptance has been duly executed and delivered by it and constitutes the legal, valid and
binding obligation of the Assignor, enforceable against the Assignor in accordance with the terms hereof, subject, as to enforcement, to bankruptcy, insolvency, moratorium, reorganization and other laws of general application relating to or
affecting creditors’ rights and to general equitable principles. 
  

 3 

 (b) The Assignor makes no representation or warranty and assumes no responsibility with
respect to any statements, warranties or representations made in or in connection with the Credit Agreement or the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Credit Agreement or any other instrument or
document furnished pursuant thereto. The Assignor makes no representation or warranty in connection with, and assumes no responsibility with respect to, the solvency, financial condition or statements of any Borrower, or the performance or
observance by any Borrower, of any of its obligations under the Credit Agreement or any other instrument or document furnished in connection therewith. 
 (c) The Assignee represents and warrants that (i) it is duly organized and existing and it has full power and authority to take, and has taken, all action necessary to execute and deliver this
Assignment and Acceptance and any other documents required or permitted to be executed or delivered by it in connection with this Assignment and Acceptance, and to fulfill its obligations hereunder; (ii) no notices to, or consents,
authorizations or approvals of, any Person are required (other than any already given or obtained) for its due execution, delivery and performance of this Assignment and Acceptance; and apart from any agreements or undertakings or filings required
by the Credit Agreement, no further action by, or notice to, or filing with, any Person is required of it for such execution, delivery or performance; (iii) this Assignment and Acceptance has been duly executed and delivered by it and
constitutes the legal, valid and binding obligation of the Assignee, enforceable against the Assignee in accordance with the terms hereof, subject, as to enforcement, to bankruptcy, insolvency, moratorium, reorganization and other laws of general
application relating to or affecting creditors’ rights and to general equitable principles; and (iv) it is an Eligible Assignee. 
 9. Further Assurances. 
 The Assignor and the Assignee each hereby agree to
execute and deliver such other instruments, and take such other action, as either party may reasonably request in connection with the transactions contemplated by this Assignment and Acceptance, including the delivery of any notices or other
documents or instruments to the Borrowers or the Administrative Agent, which may be required in connection with the assignment and assumption contemplated hereby. 
 10. Miscellaneous. 
 (a) Any amendment or waiver of any provision of this
Assignment and Acceptance shall be in writing and signed by the parties hereto. No failure or delay by either party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof and any waiver of any breach of the
provisions of this Assignment and Acceptance shall be without prejudice to any rights with respect to any other or further breach thereof. 
 (b) All payments made hereunder shall be made without any set-off or counterclaim. 
 (c) Except as otherwise agreed in writing between the Assignor and Assignee, the Assignor and the Assignee shall each pay its own costs and expenses incurred in connection with the negotiation, preparation, execution and performance of this
Assignment and Acceptance. 
 (d) This Assignment and Acceptance may be executed in any number of counterparts and all of such
counterparts taken together shall be deemed to constitute one and the same instrument. 
 (e) THIS ASSIGNMENT AND ACCEPTANCE
SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF GEORGIA. The Assignor and the Assignee each irrevocably submits to the non-exclusive jurisdiction of any State or Federal court sitting in The State of Georgia over any
suit, action or proceeding arising out of or relating to this Assignment and Acceptance and irrevocably agrees that all claims in respect of such action or proceeding may be heard and determined in such State or Federal court. Each party to this
Assignment and Acceptance hereby irrevocably waives, to the fullest extent it may effectively do so, the defense of an inconvenient forum to the maintenance of such action or proceeding. 
  

 4 

 (f) THE ASSIGNOR AND THE ASSIGNEE EACH HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE
ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS ASSIGNMENT AND ACCEPTANCE, THE CREDIT AGREEMENT, ANY RELATED DOCUMENTS AND AGREEMENTS OR ANY COURSE OF
CONDUCT, COURSE OF DEALING, OR STATEMENTS (WHETHER ORAL OR WRITTEN). 
 IN WITNESS WHEREOF, the Assignor and the Assignee have
caused this Assignment and Acceptance to be executed and delivered by their duly authorized officers as of the date first above written. 
  

			
	THE CIT GROUP/BUSINESS CREDIT, INC.
		
	By:	 	/s/ Carmen Caporrino
	Name:	 	Carmen Caporrino
	Title:	 	Vice President
	
	Address for Notices:
	
	The CIT Group/Business Credit, Inc.
	11 West 42nd Street
	New York, NY 10036
	Attn:	 	Evelyn Kusold
	
	WACHOVIA BANK, NATIONAL ASSOCIATION
		
	By:	 	/s/ Lynn E. Culbreath
	Name:	 	Lynn E. Culbreath
	Title:	 	Senior Vice President
	
	Address for Notices:
	
	Wachovia Bank, National Association
	100 South Ashley Dr., Suite 1000
	Tampa, Florida 33602
	Attn:	 	Jack Nieman and Lynn E. Culbreath

  

 5 

 SCHEDULE 1 
 to 
 ASSIGNMENT AND ACCEPTANCE 
 NOTICE OF ASSIGNMENT AND ACCEPTANCE 
 September 16, 2009 
 Bank of America, N.A. 
 300 Galleria Parkway, N.W. 
 Suite 800 

Atlanta, Georgia 30339 
 Attn: Business
Credit-Account Executive 
 Kforce Inc. 
 and the other Borrowers (as hereinafter defined) 
 1001 E. Palm Avenue, 4th floor 
 Tampa, Florida 33605 
 Attention: Ms. Judy Genshino-Kelly, 
 Assistant Treasurer 
  

	 	Re:	Kforce Inc. 

 Ladies and Gentlemen: 

We refer to the Second Amended and Restated Credit Agreement dated as of October 2, 2006 (as amended, amended and restated, modified,
supplemented or renewed from time to time the “Credit Agreement”) among Kforce Inc. and certain of its Subsidiaries, as borrowers (the “Borrowers”), the affiliates of the Borrowers party thereto, the Lenders
referred to therein and Bank of America, N.A., as Administrative Agent for the Lenders (the “Administrative Agent”). Terms defined in the Credit Agreement are used herein as therein defined. 
 1. We hereby give you notice of, and request the Administrative Agent’s consent to, the assignment by The CIT Group/Business Credit,
Inc. (the “Assignor”) to Wachovia Bank, National Association (the “Assignee”) of 57.1428571% of the right, title and interest of the Assignor in and to the Credit Agreement (including the right, title and interest
of the Assignor in and to the Commitments of the Assignor, all outstanding Loans made by the Assignor and the Assignor’s participation in the Letters of Credit pursuant to the Assignment and Acceptance Agreement attached hereto (the
“Assignment and Acceptance”). We understand and agree that the Assignor’s Commitment, as of September 16, 2009 (prior to giving effect to the Assignment and Acceptance), is $35,000,000, the aggregate amount of its
outstanding Loans is $4,015,000.00, and its participation in L/C Obligations is $1,227,524.32. 
 2. The Assignee agrees that,
upon receiving the consent of the Administrative Agent, the Assignee will be bound by the terms of the Credit Agreement as fully and to the same extent as if the Assignee were the Lender originally holding such interest in the Credit Agreement.

 3. The following administrative details apply to the Assignee: 
  

					
	(A)	    	Notice Address:	    	Assignee Name:
		    		    	Wachovia Bank, National Association
			
		    		    	Assignee Address:
		    		    	Wachovia Bank, National Association
		    		    	100 South Ashley Dr., Suite 1000
		    		    	Tampa, Florida 33602
		    		    	Attn: Jack Nieman and Lynn E. Culbreath
		    		    	Facsimile No.: (813) 225-4330
			
	(B)	    	Payment Instructions:	    	As on file with the Administrative Agent

 4. You are entitled to rely upon the representations, warranties and covenants of
each of the Assignor and Assignee contained in the Assignment and Acceptance. 
 5. Pursuant to Section 11.2 of the Credit
Agreement, Assignee hereby requests, and instructs the Administrative Agent to request from the Borrowers, a replacement promissory note evidencing the Assignee’s Commitment (after giving effect to the Assignment and Acceptance) in the amount
set forth in Section 1(c) of the Assignment and Acceptance. 
 IN WITNESS WHEREOF, the Assignor and the Assignee have
caused this Notice of Assignment and Acceptance to be executed by their respective duly authorized officials, officers or agents as of the date first above mentioned. 
  

			
	Very truly yours,
	
	THE CIT GROUP/BUSINESS CREDIT, INC.
		
	By:	 	/s/ Carmen Caporrino
	Title:	 	Vice President
	
	WACHOVIA BANK, NATIONAL ASSOCIATION
		
	By:	 	/s/ Lynn E. Culbreath
	Title:	 	Senior Vice President

  

			
	ACKNOWLEDGMENT AND
ASSIGNMENT CONSENTED TO:
	
	Bank of America, N.A.,
as Administrative Agent
		
	By:	 	/s/ Andrew A. Doherty
	Title:	 	Senior Vice President

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]